Probably before Thanksgiving, or Christmas at the latest. At least Sanofi tried hard to prevent layoffs by bridging them in other divisions. It is definitely commendable. It wouldn't surprise me if that's part of the reason Carol H got the axe, from keeping them on board.
Lol Upper leadership has been telling us for months to take another internal job asap. You think that for $h.it and giggles? And think about Sanofi's past track record for launches. What did you think was going to happen?
Tolebrutinib is a BTK inibitor, like the SOC of anti-CD20 antibodies a drug class initially used in oncology (e.g. Imbruvica, ibrutinib). Therefore despite efficacy side effects like the liver issues plus cardiovascular risks and e.g. skin cancers are a challenge. The warnings list would not be shorter, than that of Aubagio or Lemtrada. Probably in MS not such a problem, but for Rilzabrutinib in skin indication, the dermatologist would appreciate to screen for skin cancer ever year. In addition a RMP or even CRL by the FDA could be expected. Why was silence regarding Tolebrutinib in the Q3 investor event and the share price dropped by almost 20%. And next generation, high specifity seems not to make a difference in the lastest BTK inhibitor generations, for example Pirtobrutinib was recently approved with these warnings: • Infections: Monitor for signs and symptoms of infection, evaluate promptly, and treat. • Hemorrhage: Monitor for bleeding and manage appropriately. • Cytopenias: Monitor complete blood counts during treatment. • Atrial Fibrillation and Atrial Flutter: Monitor for symptoms of arrhythmias and manage appropriately. • Second Primary Malignancies: Other malignancies have developed, including skin cancers and other carcinomas. Monitor and advise patients to use sun protection. • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception.
Roche recently published partial hold of its BTKi studies by FDA, only Novartis seems to have no safety issues
